Adjusted FFO fell to $15.3M from $17M. Full-year 2026 adjusted FFO guidance rose 11.5% from original guidance to $0.57–$0.59 per diluted share.

This is an engineering concept and a research bench, not a medical device. Prototype results must not be used for diagnosis, treatment decisions, or changing medication doses. The idea: make blood ...

Have you ever heard this during a ward handover?"The patient is voiding on their own. There was 100mL of residual urine, so I ...